sigma expands generic pipeline agreement with

Sigma expands generic pipeline agreement with Arrow
18:53, Thursday, 12 April 2007

Sydney - Thursday - April 12: (RWE Australian Business News) -
Sigma Pharmaceuticals Ltd (ASX code: SIP) has reached agreement with
Arrow Group ApS for an additional pipeline of generic drugs, "to
consolidate its position as the leading generic player in Australasia".
The expanded pipeline arrangement provides for a minimum of 25
additional products, on top of the 60 drugs originally agreed, to be
delivered to Sigma within five years from the date of this amendment.
Sigma managing director and CEO Mr Elmo de Alwis said, "We are
delighted with the progress that has been made with the registration and
commercialisation of the Arrow Group pipeline.
"When we entered into the merger 18 months ago we anticipated it
would take five years to hit the 60-product milestones.
"With 54 products already at that stage and another 25 products
to be submitted to TGA by the end of 2007, followed by another 17 in
2008, the value to Sigma shareholders of access to Arrow's pipeline is
far greater and has been achieved in a much shorter timeframe than we
had anticipated."
Arrow Group is an international generic company based in
Denmark, with subsidiaries throughout Europe, North America and Asia.

*****